No Prescription |
 |
 | ||
|
VIRAMUNE Generic Nevirapine |
|
| ||
No Prescription » Prescription Drugs 17 » VIRAMUNE Generic Nevirapine This medication is used with other medications to help control your HIV infection thereby improving your quality of life. It also lowers your risk of getting HIV disease complications (e.g. new infections cancer). Nevirapine belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors.Nevirapine is not a cure for HIV infection and it does not prevent the spread of HIV to others through sexual contact or blood contamination (e.g. sharing used needles).How to use Nevirapine OralTake this medication by mouth with or without food usually once daily for the first 14 days when you first start treatment then twice daily or as directed by your doctor.Dosage is based on your age weight sex T-cell count medical condition other medications and response to therapy.It is very important to continue taking this medication (and other HIV medications) exactly as prescribed by your doctor.This medication works best when the amount of drug in your body is kept at a constant level. Therefore take this drug at evenly spaced intervals. To help you remember take it at the same times each day.Do not take more or less of this drug than prescribed or stop taking it (or other HIV medicines) even for a short time unless directed to do so by your doctor. Skipping or changing your dose without approval from your doctor may cause the amount of virus to increase make the infection more difficult to treat (resistant) or worsen side effects. If HIV becomes resistant to this medication it might also be resistant to other HIV medications. Buy VIRAMUNE Generic Nevirapine and other Prescription Drugs 17 products online at Medstore. 634
About VIRAMUNE Generic Nevirapine: Product Type: Prescription Drugs 17 VIRAMUNE ( Generic Nevirapine ) VIRAMUNE (Generic Nevirapine) Generic Nevirapine 200mg Tabs 30 (3 x 10) Generic Nevirapine VIRAMUNE
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
